Skip to content

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan P. Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Péter Merkely, Stephen James Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr P. Ponikowski, Michele Senni, David Sim, Jindřich Špinar, Iain B Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Peter E. Carson, Carolyn S.P. Lam, Nikolaus Marx, Cordula Zeller, Naveed A. Sattar, Waheed Jamal, Sven Schnaidt, Janet M. Schnee, Martina Brueckmann, Stuart Pocock, Faiez M. Zannad, Milton Packer

New England Journal of Medicine · 2021 · 5,211 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Anker, S. D., Butler, J., Filippatos, G. S., Ferreira, J. P., Bocchi, E. A., Böhm, M., Rocca, H. B., Choi, D., Chopra, V., Chuquiure‐Valenzuela, E., Giannetti, N., Gómez‐Mesa, J. E., Janssens, S. P., Januzzi, J. L., González‐Juanatey, J. R., Merkely, B. P., Nicholls, S. J., Perrone, S. V., Piña, I. L., … Packer, M. (2021). Empagliflozin in heart failure with a preserved ejection fraction. New England Journal of Medicine, 385(16), 1451–1461. https://doi.org/10.1056/nejmoa2107038

In text: (Anker et al., 2021)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Sodium-glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. METHODS: In this double-blind trial, we randomly assigned 5988 patients with class II-IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. RESULTS: Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin. CONCLUSIONS: Empagliflozin reduced the combined risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Preserved ClinicalTrials.gov number, NCT03057951).

  1. Harmonizing the Metabolic Syndrome2009
  2. 2013 ACCF/AHA Guideline for the Management of Heart Failure2013
  3. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging2015
  4. Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure1991
  5. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction2019

Metadata from OpenAlex (CC0). Citations are generated from the published record.